Trial Profile
A pharmacogenomics study for adverse effects and clinical outcome to S-1 in gastric cancer patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2011
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Pharmacogenomic; Therapeutic Use
- 11 Feb 2011 New trial record